

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 21, 2006 Signature: (Jeanne M. DiGiorgio)

IFW \$  
Docket No.: CDJ-301  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Tibor Keler, Ph.D., J.D. *et al.*

Application No.: 10/769144

Confirmation No.: 9318

Filed: January 30, 2004

Art Unit: 1644

For: ANTIBODY VACCINE CONJUGATES AND  
USES THEREFOR

Examiner: Kim Yunsoo

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)**

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicants have not submitted copies of each cited U.S. patent and U.S. patent application in accordance with 37 CFR 1.98(a)(2)(ii). Applicants submit herewith copies of foreign patents and non-patent references in accordance with 37 CFR 1.98(a)(2).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that


such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.


Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CDJ-301.

Dated: September 21, 2006

JMD/JGS/mch

Respectfully submitted,

By   
Jeanne M. DiGiorgio  
Registration No.: 41,710  
LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, Massachusetts 02109  
(617) 227-7400  
(617) 742-4214 (Fax)  
Attorney/Agent For Applicant



PTO/SB/21 (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/769,144-Conf. #9318
	Filing Date	January 30, 2004
	First Named Inventor	Tibor KELER
	Art Unit	1644
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	CDJ-301

## ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard PTO form SB/08 Certificate of Mailing Copies of References Fifty-eight (58) References
<b>Remarks</b>		


## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	LAHIVE & COCKFIELD, LLP		
Signature			
Printed name	Jeanne M. DiGiorgio		
Date	September 21, 2006	Reg. No.	41,710

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 21, 2006

Signature: (Jeanne M. DiGiorgio)



PTO/SB/17 (07-06)  
Approved for use through 01/31/2007. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Effective on 12/08/2004.</b> Pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).		<b>Complete if Known</b>	
<b>FEE TRANSMITTAL</b> <b>For FY 2005</b>		Application Number	10/769,144-Conf. #9318
		Filing Date	January 30, 2004
		First Named Inventor	Tibor KELER
		Examiner Name	Not Yet Assigned
		Art Unit	1644
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Attorney Docket No.	CDJ-301
<b>TOTAL AMOUNT OF PAYMENT</b>		<b>(\$)</b>	<b>180.00</b>

**METHOD OF PAYMENT (check all that apply)**

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): \_\_\_\_\_  
☒ Deposit Account Deposit Account Number: **12-0080** Deposit Account Name: **Lahive & Cockfield, LLP**

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee  
☒ Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

**2. EXCESS CLAIM FEES**

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

**Total Claims**      **Extra Claims**      **Fee (\$)**      **Fee Paid (\$)**  
\_\_\_\_\_ - = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_

HP = highest number of total claims paid for, if greater than 20.

**Indep. Claims**      **Extra Claims**      **Fee (\$)**      **Fee Paid (\$)**  
\_\_\_\_\_ - = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_

HP = highest number of independent claims paid for, if greater than 3.

**Multiple Dependent Claims**

**Fee (\$)**      **Fee Paid (\$)**  
\_\_\_\_\_

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

**Total Sheets**      **Extra Sheets**      **Number of each additional 50 or fraction thereof**      **Fee (\$)**      **Fee Paid (\$)**  
\_\_\_\_\_ - 100 = \_\_\_\_\_ / 50 \_\_\_\_\_ (round up to a whole number) x \_\_\_\_\_ = \_\_\_\_\_

**4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)


Other (e.g., late filing surcharge): **1806 Submission of an Information Disclosure Statement**      **180.00**

<b>SUBMITTED BY</b>			
Signature		Registration No. (Attorney/Agent)	41,710
Name (Print/Type)	Jeanne M. DiGiorgio	Telephone	(617) 227-7400
		Date	September 21, 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 21, 2006

Signature: (Jeanne M. DiGiorgio)



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

### Complete if Known

Application Number	10/769,144-Conf. #9318
Filing Date	January 30, 2004
First Named Inventor	Tibor KELER
Art Unit	1644
Examiner Name	Not Yet Assigned
Attorney Docket Number	CDJ-301

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1*	US-4,474,893	10-02-1984	Reading	
	A2*	US-4,946,778	08-07-1990	Ladner et al.	
	A3*	US-4,954,617	09-04-1990	Fanger et al.	
	A4*	US-5,455,030	10-03-1995	Ladner et al.	
	A5*	US-5,476,786	12-19-1995	Huston	
	A6*	US-5,545,807	08-13-1996	Surani et al.	
	A7*	US-5,876,917	03-02-1999	Hart et al.	
	A8*	US-5,922,845	07-13-1999	Deo et al.	
	A9*	US-6,080,409	06-27-2000	Laus et al.	
	A10*	US-6,277,959	08-21-2001	Valladeau et al.	
	A11*	US-6,340,569	01-22-2002	Ball et al.	
	A12*	US-6,432,666	08-13-2002	Hart et al.	
	A13*	US-6,479,247-A1	11-12-2002	Hart et al.	
	A14*	US-20040001853-A1	01-01-2004	George et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO-86/01533-A1	03-13-1986	Celltech Limited		
	B2	WO-88/00052-A1	01-14-1988	Trustees of Dartmouth College		
	B3	WO-92/07579-A1	05-14-1992	The Children's Medical Center Corporation		
	B4	WO-92/03918-A1	03-19-1992	Genpharm International, Inc.		
	B5	WO-93/04187-A1	03-04-1993	Medical Research Council		
	B6	WO-93/12227-A1	06-24-1993	Genpharm International, Inc.		
	B7	WO-94/10332-A1	05-11-1994	Medarex, Inc.		
	B8	WO-95/15340-A1	06-08-1995	The Board of Trustees of Leland Stanford Junior University		
	B9	WO-96/23882-A1	08-08-1996	The Rockefeller University		
	B10	WO-97/45449-A1	12-04-1997	Hart, Derek et al.		
	B11	WO-98/24884-A1	06-11-1998	Genpharm International		
	B12	WO-98/15579-A1	04-16-1998	Canterbury Health Limited		
	B13	WO-99/02562-A1	01-21-1999	Schering Corporation		
	B14	WO-99/16455-A1	04-08-1999	The Austin Research Institute		
	B15	WO-99/24554-A2	05-20-1999	University of Pittsburgh		
	B16	WO-99/47673-A2	09-23-1999	Schering Corporation		
	B17	WO-99/55369-A1	11-04-1999	Smithkline Beecham Corporation		
	B18	WO-99/58678-A2	11-18-1999	Micromet GmbH		
	B19	WO-00/00156-A2	01-06-2000	Trustees of Dartmouth College		
	B20	WO-00/00592-A1	01-06-2000	Bae, Yong Soo et al.		
	B21	WO-00/18803-A2	04-06-2000	Schering Corporation		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/769,144-Conf. #9318
				Filing Date	January 30, 2004
				First Named Inventor	Tibor KELER
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	CDJ-301

	B22	WO-00/63251-A1	10-26-2000	Katholieke Universiteit Nmegen		
	B23	WO-01/25492-A1	04-12-2001	Biosite Diagnostics, Inc. et al.		
	B24	WO-03/040169-A2	05-15-2003	Medarex, Inc.		
	B25	WO-04/026326-A2	04-01-2004	Stichting Katholieke Universiteit		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Apostolopoulos, Vasso et al, "Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses," <i>Vaccine</i> , Vol. 18:3174-3184 (2000)	
	C2	Berard, Frederic et al, "Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells," <i>J. Exp. Med.</i> , Vol. 192(11):1535-1543 (2000)	
	C3	Berlyn, Kathleen A. et al, "Generation of CD4 <sup>+</sup> and CD8 <sup>+</sup> T Lymphocyte Responses by Dendritic Cells Armed with PSA/Anti-PSA (Antigen/Antibody) Complexes," <i>Clinical Immunology</i> , Vol. 101(3):276-283 (2001)	
	C4	Bird, Robert E. et al, "Single-Chain Antigen-Binding Proteins," <i>Science</i> , Vol. 242(4877):423-426 (1988)	
	C5	Brennan, Maureen et al, "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments," <i>Science</i> , Vol. 229:81-83 (1985)	
	C6	Chien, Nadine C. et al, "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86:5532-5536 (1989)	
	C7	Frleta, Davor et al, "Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo," <i>International Immunopharmacology</i> , Vol. 1:265-275 (2001)	
	C8	Galfre, G. et al, "Antibodies to major histocompatibility antigens produced by hybrid cell lines," <i>Nature</i> , Vol. 266(7):550-552 (1977)	
	C9	Geissmann, Frédéric et al, "A Subset of Human Dendritic Cells Expresses IgA Fc Receptor (CD89), Which Mediates Internalization and Activation Upon Cross-Linking by IgA Complexes," <i>The Journal of Immunology</i> , Vol. 166:346-352 (2001)	
	C10	Glennie, Martin J. et al, "Preparation and Performance of Bispecific F(ab'γ)2 Antibody Containing Thioether-Linked Fab'γ Fragments," <i>The Journal of Immunology</i> , Vol. 139(7):2367-2375 (1987)	
	C11	Hawiger, Daniel et al, "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions In Vivo," <i>J. Exp. Med.</i> , Vol. 194(6):769-779 (2001)	
	C12	He, Li-Zhen et al, "A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin β," <i>Clinical Cancer Research</i> , Vol. 10:1920-1927 (2004)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/769,144-Conf. #9318
				Filing Date	January 30, 2004
				First Named Inventor	Tibor KELER
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	CDJ-301

C13	He, Lizhen et al, "An Antigen Presenting Cell-Targeted Cancer Vaccine that Elicits CD4 and CD8 Effector Responses to the hCG $\beta$ Tumor-Associated Antigen," <i>Proceedings of the American Association for Cancer Research</i> , Vol. 44, 2nd ed., pg. 167 (2003)
C14	Karpovsky, Boris et al, "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fc $\gamma$ Receptor Antibodies," <i>Journal of Experimental Medicine</i> , Vol. 160:1686-1701 (1984)
C15	Kawakami, Yutaka et al, "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma," <i>Journal of Immunotherapy</i> , Vol. 21(4):237-246 (1998)
C16	Kobayashi, Hiroyuki et al, "Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody," <i>Protein Engineering</i> , Vol. 12(10):879-884 (1999)
C17	Liu, Margaret A. et al, "Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82:8648-8652 (1985)
C18	Lonberg, Nils et al, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , Vol. 368:856-859 (1994)
C19	Monteiro, Renato C. et al, "Molecular Heterogeneity of Fc $\alpha$ Receptors Detected by Receptor-Specific Monoclonal Antibodies," <i>The Journal of Immunology</i> , Vol. 148(6):1764-1770 (1992)
C20	Noorman, Femke et al, "Monoclonal antibodies against the human mannose receptor as a specific marker in flow cytometry and immunohistochemistry for macrophages," <i>Journal of Leukocyte Biology</i> , Vol. 61:63-72 (1997)
C21	Nouri-Shirazi, Mahyar et al, "Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Response," <i>The Journal of Immunology</i> , Vol. 165:3797-3803 (2000)
C22	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies," <i>Behring Inst. Mitt.</i> , Vol. 78:118-132 (1985)
C23	Potter, Kathleen N. et al, "Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-34-Encoded Igs in Recognition of the Red Blood Cell I Antigen," <i>The Journal of Immunology</i> , Vol. 169:3777-3782 (2002)
C24	Ramakrishna, Vanky et al, "Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules," <i>The Journal of Immunology</i> , Vol. 172:2845-2852 (2004)
C25	Ramakrishna, Venky et al, "Synergistic Role of TLR Agonists in T Cell-Mediated Immunity Induced by Mannose Receptor Antibody Targeting of Tumor Antigens to Human DCs," <i>J. Immunother.</i> , Vol. 28(6):658 (2005)
C26	Sallusto, Federica et al, "Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products," <i>J. Exp. Med.</i> , Vol. 182:389-400 (1995)
C27	Tempest, Philip R. et al, "A Humanized Anti-Tumor Necrosis Factor- $\alpha$ Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> , Vol. 13(3):183-190 (1994)
C28	Tjoa, Benjamin A. et al, "Development of dendritic-cell based prostate cancer vaccine," <i>Immunology Letters</i> , Vol. 74:87-93 (2000)
C29	Tüting, Thomas et al, "Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN- $\alpha$ ," <i>The Journal of Immunotherapy</i> , Vol. 160:1139-1147 (1998)
C30	Wallace, Paul K. et al, "Exogenous antigen targeted to Fc $\gamma$ RI on Myeloid cells is presented in association with MHC class I," <i>Journal of Immunological Methods</i> , Vol. 248:183-194 (2001)
C31	Wang, Hui et al, "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization," <i>PNAS</i> , Vol. 96(2):847-852 (2000)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/769,144-Conf. #9318
				Filing Date	January 30, 2004
				First Named Inventor	Tibor KELER
				Art Unit	1644
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	CDJ-301
Sheet	4	of	4		

	C32	Ward, E. Sally et al, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , Vol. 341:544-546 (1989)	
	C33	You, Zhaoyang et al, "Targeting Dendritic Cells to Enhance DNA Vaccine Potency," <i>Cancer Research</i> , Vol. 61:3704-3711 (2001)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/769,144

Attorney Docket No.: CDJ-301

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on September 21, 2006  
Date

Signature

Jeanne M. DiGiorgio

Typed or printed name of person signing Certificate

41,710  
Registration Number, if applicable

(617) 227-7400  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard  
Transmittal (1 page)  
Fee Transmittal (1 page, in duplicate)  
Supplemental Information Disclosure Statement (2 pages)  
PTO form SB/08 (72 References) (4 pages)  
Copies of Fifty-eight (58) References